These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28096874)

  • 1. Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study.
    Lee JS; Kwon JS; Kim D; Kim SW; Kim JJ; Kim JH; Nam HJ; Ryu S; Park IH; An SK; Oh HS; Won S; Lee K; Lee KY; Lee SH; Lee YS; Yi JS; Hong KS; Joo YH
    Psychiatry Investig; 2017 Jan; 14(1):44-50. PubMed ID: 28096874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
    Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia.
    Lee NY; Roh MS; Kim SH; Jung DC; Yu HY; Sung KH; Chung IW; Youn T; Kang UG; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2013 Mar; 28(2):71-9. PubMed ID: 23211493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics.
    Ventriglio A; Baldessarini RJ; Vitrani G; Bonfitto I; Cecere AC; Rinaldi A; Petito A; Bellomo A
    Front Psychiatry; 2018; 9():744. PubMed ID: 30700975
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antipsychotic Treatment of the Adult Patient in the Acute Phase of Schizophrenia].
    Bohórquez Peñaranda A; Gómez Restrepo C; García Valencia J; Jaramillo González LE; de la Hoz AM; Arenas Á; Tamayo Martínez N
    Rev Colomb Psiquiatr; 2014; 44 Suppl 1():13-28. PubMed ID: 26576459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
    Ono S; Sugai T; Suzuki Y; Yamazaki M; Shimoda K; Mori T; Ozeki Y; Matsuda H; Sugawara N; Yasui-Furukori N; Okamoto K; Sagae T; Someya T
    BMC Psychiatry; 2018 Jun; 18(1):180. PubMed ID: 29879941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
    Said MA; Hatim A; Habil MH; Zafidah W; Haslina MY; Badiah Y; Ramli MA; Ananjit S; Sapini Y; Shah M; Mahmud B; Bulgiba A; Hairi NN
    Prev Med; 2013; 57 Suppl():S50-3. PubMed ID: 23337566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.
    Bou Khalil R
    Clin Neuropharmacol; 2012; 35(3):141-7. PubMed ID: 22592510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
    Zhang Y; Wang Q; Reynolds GP; Yue W; Deng W; Yan H; Tan L; Wang C; Yang G; Lu T; Wang L; Zhang F; Yang J; Li K; Lv L; Tan Q; Li Y; Yu H; Zhang H; Ma X; Yang F; Li L; Chen Q; Wei W; Zhao L; Wang H; Li X; Guo W; Hu X; Tian Y; Ren H; Ma X; Coid J; Zhang D; Li T;
    J Clin Psychiatry; 2020 Mar; 81(3):. PubMed ID: 32237292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and trends of metabolic syndrome in Korea: Korean National Health and Nutrition Survey 1998-2001.
    Park HS; Kim SM; Lee JS; Lee J; Han JH; Yoon DK; Baik SH; Choi DS; Choi KM
    Diabetes Obes Metab; 2007 Jan; 9(1):50-8. PubMed ID: 17199718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder.
    Chiu CC; Chen CH; Huang MC; Chen PY; Tsai CJ; Lu ML
    J Clin Psychopharmacol; 2012 Oct; 32(5):585-92. PubMed ID: 22926590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital.
    Oh S; Lee TY; Kim M; Kim SH; Lee S; Cho S; Kim JH; Kwon JS
    NPJ Schizophr; 2020 Nov; 6(1):32. PubMed ID: 33214559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.
    Vancampfort D; Stubbs B; Mitchell AJ; De Hert M; Wampers M; Ward PB; Rosenbaum S; Correll CU
    World Psychiatry; 2015 Oct; 14(3):339-47. PubMed ID: 26407790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of metabolic syndrome among patients with schizophrenia in Japan.
    Sugawara N; Yasui-Furukori N; Sato Y; Umeda T; Kishida I; Yamashita H; Saito M; Furukori H; Nakagami T; Hatakeyama M; Nakaji S; Kaneko S
    Schizophr Res; 2010 Nov; 123(2-3):244-50. PubMed ID: 20850274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.